tyrosine kinase inhibitors (EGFRTKIs) show a clinical benefit when used to treat patients with EGFR-mutated non-small cell lung cancer (NSCLC), but this treatment unfortunately fails in patients with ... resistant…
only 10%. Current studies have focused on the importance of Cyclin D1, E-cadherin, EGFR, HER- 2, Ki67, and p53 immunomarkers in the development and prognosis ... other immunomarkers Cyclin D1, E-cadherin, EGFR, Ki67…
Cell-surface receptors (e.g., EGFR and integ-rin) and their interactions play determining roles in signal transduction and cytoskeletal activation, which affect cell attachment/detachment, invasion, motility…
Epidermal growth factor receptor (EGFR) inhibitor gefitinib (Iressa) is a synthetic anilinoquinazoline, which is extensively used for treating non small cell lung cancer. Apart from its anti-cancer activities against…
antibodies which can target to tumor cells by a monoclonal antibody or antibody fragment. EGFR has been involved in the development and progression of a diverse type of solid tumors ... Recently studies indicated that…
Introduction: Epidermal Growth Factor Receptor (EGFR) was shown to be highly expressed in many types of human cancer, among others, in breast cancers. EGFR overexpression correlates with advanced stage ... with poor…
circulating tumor DNA may predict resistance to first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors before CT-confirmed progression. Our objective was to evaluate dynamic changes in plasma…
Management of non-small cell lung cancer (NSCLC) with EGFR exon 20 mutations is an unmet medical need. Poziotinib is a potent irreversible tyrosine kinase inhibitor of wild type ... EGFR and HER2 exon 20 insertion…
tyrosine kinase inhibitors (TKIs) to selectively target tumors with activating epidermal protein receptor (EGFR) mutations marked a revolutionary milestone within the management of non–small-cell carcinoma (NSCLC) and…
Background: Epidermal growth factor receptor (EGFR) inhibitor gefitinib (Iressa) is a synthetic anilinoquinazoline, which is extensively used for treating non small cell lung cancer. Apart from its anti-cancer…
Introduction: Epidermal growth factor receptor (EGFR) was shown to be highly expressed in many types of human cancer, among others, in breast cancers. EGFR overexpression correlates with advanced stage ... with poor…
Objectives: We aimed to investigate the discriminative value of texture feature in EGFR mutation of lung adenocarcinoma and prognostic value of texture features using 18Fluorine-Fluorodeoxyglucose (18F-FDG) Positron…
growth factor receptor-tyrosine kinase inhibitors resistance in non-small cell lung cancer harboring EGFR mutations has not been elucidated. To explore this relationship, we utilized an EGFR-TKIs sensitizing ... EGFR…
accounts for 85% of all lung cancers and 60% of these have wild-type EGFR (wtEGFR) overexpression, which portends a poor prognosis. However, agents targeting EGFR have limited utility ... various development stages and…
accounts for 85% of all lung cancers and 60% of these have wild-type EGFR (wtEGFR) overexpression, which portends a poor prognosis. However, agents targeting EGFR have limited utility ... various development stages and…
modifies the phosphorylation of receptor tyrosine kinases, notably epidermal growth factor receptor (EGFR) and the âÂ?Â?undruggableâÂ? Ras oncogene promoting the growth of glioblastoma cells. The first phase ... Shp2…
based chemotherapy. We report partial response in metastatic large cell neuroendocrine tumor with an EGFR mutation. Moreover, targeted next generation sequencing analysis upon disease progression identified possible…
This study has been based on the improvements observed in predominantly diabetic patients with EGFR falling below normal, leading to stage III and stage IV renal damage. The study consisted ... review of 82 patients’…
been an unignorable bottleneck for patients benefiting from epidermal growth factor receptortyrosine kinase inhibitor (EGFR-TKI). Ginsenoside Rg3 is an anti-angiogenic agent which can down-regulate expression of…
blood–brain barrier (BBB). By chemical library screening, we identified epidermal growth factor receptor (EGFR) as a contributor to E. coli invasion of the BBB in vitro and in vivo ... direct evidence that CNS-infecting…
been proven effective in stage IV NSCLC. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), such as gefitinib and erlotinib, is the standard first-line treatment for stage ... small cell lung cancer…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.